Ribosomal protein RPL22/eL22 regulates the cell cycle by acting as an inhibitor of the CDK4-cyclin D complex

核糖体蛋白RPL22/eL22通过抑制CDK4-细胞周期蛋白D复合物来调控细胞周期。

阅读:2
作者:Neylen Del Toro ,Ana Fernandez-Ruiz ,Lian Mignacca ,Paloma Kalegari ,Marie-Camille Rowell ,Sebastian Igelmann ,Emmanuelle Saint-Germain ,Mehdi Benfdil ,Stéphane Lopes-Paciencia ,Léa Brakier-Gingras ,Véronique Bourdeau ,Gerardo Ferbeyre ,Frédéric Lessard

Abstract

Senescence is a tumor suppressor program characterized by a stable growth arrest while maintaining cell viability. Senescence-associated ribogenesis defects (SARD) have been shown to regulate senescence through the ability of the ribosomal protein S14 (RPS14 or uS11) to bind and inhibit the cyclin-dependent kinase 4 (CDK4). Here we report another ribosomal protein that binds and inhibits CDK4 in senescent cells: L22 (RPL22 or eL22). Enforcing the expression of RPL22/eL22 is sufficient to induce an RB and p53-dependent cellular senescent phenotype in human fibroblasts. Mechanistically, RPL22/eL22 can interact with and inhibit CDK4-Cyclin D1 to decrease RB phosphorylation both in vitro and in cells. Briefly, we show that ribosome-free RPL22/eL22 causes a cell cycle arrest which could be relevant during situations of nucleolar stress such as cellular senescence or the response to cancer chemotherapy. Keywords: CDK4; RPL22/eL22; RPS14/uS11; Ribosome biogenesis; cyclin D1; senescence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。